Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Background: Most people with tuberculosis (TB) feel better after starting treatment. But for some people, the opposite happens. They may feel better at first, but then suddenly get worse. This is a paradoxical reaction. Researchers want to better understand what causes this reaction and what happens after someone has it.

Objective: To learn about paradoxical reactions to TB treatment.

Eligibility: Adults 18 and older diagnosed with confirmed or suspected TB and currently on treatment for at least 2 weeks, with or without signs/symptoms of a paradoxical inflammatory reaction.

Design: Participants will be screened with a physical exam and medical history. They will give blood and urine samples. Eligible participants will visit the NIH Clinical Center 3 times over 6 to 18 months. Each visit will take 7 hours to complete; visits may be scheduled over more than 1 day. Participants may have more visits if their TB symptoms change. Participants will give blood, urine, and sputum samples. They will have adverse event assessments. They will have 2 to 3 positron emission tomography/computed tomography (PET/CT) scans. PET/CT scans make pictures of the inside of the body. For this, participants will lie on a table that slides into a donut-shaped scanner. They will get a small amount of radioactive dye through an IV, which is a small plastic tube placed in a vein in the arm using a needle. Participants may have optional apheresis. For this, blood is taken from a needle in one arm. White blood cells are separated from the rest of the blood. The rest of the blood is returned through a needle in the other arm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

∙ Suspected Paradoxical Reaction Group Criteria:

• Aged greater than or equal to 18 years.

• Diagnosed with confirmed (microbiologically or with molecular methods) or suspected (clinical plus or minus histologic diagnosis) TB and currently on ATT for a minimum of 2 weeks, or have completed ATT, with at least 2 of the following signs/symptoms of a paradoxical inflammatory reaction:

‣ Recrudescent symptoms of TB after initial clinical improvement.

⁃ Change in physical exam after initial clinical improvement suggestive of new inflammatory process (e.g., lymphadenopathy or new findings on pulmonary exam).

⁃ Worsening radiographic evidence of disease after initiation of treatment, as compared with imaging prior to or earlier in treatment.

⁃ Laboratory evidence of acute inflammatory response, including the development of leukocytosis (white blood cell count \> 10,000 cells/microL) or a change of C-reactive protein (CRP) \> 5 mg/L compared to prior laboratory values.

⁃ Worsened organ function after initial clinical improvement.

• The above sign/symptom(s) cannot be explained by a newly acquired infection, clinical course of a previously recognized infectious agent, side effects of the ATT, the presence of drug resistance, or any other condition except for paradoxical reaction.

• Willingness to allow storage of blood or tissue samples for future research.

• Ability of participant to understand study requirements and give informed consent.

• Has a primary care physician and is being followed by the local Department of Health for their TB (or has plans to arrange after enrollment if enrolled early in course from inpatient transfer).

∙ Control Group Criteria:

• Aged greater than or equal to 18 years.

• Diagnosed with confirmed (microbiologically or with molecular methods) or suspected (clinical plus or minus histologic diagnosis) TB.

• Presenting 2 to 4 months after starting ATT to match timing of paradoxical reactions.

• Willingness to allow storage of blood or tissue samples for future research.

• Ability of participant to understand study requirements and give informed consent.

• Has a primary care physician and is being followed by the Department of Health for their TB (or has plans to arrange after enrollment if enrolled early in course from inpatient transfer).

Locations
United States
Maryland
National Institutes of Health Clinical Center
RECRUITING
Bethesda
Contact Information
Primary
Mary E McLaughlin, R.N.
mmclaughli@niaid.nih.gov
(301) 435-8001
Backup
Maura M Manion, M.D.
maura.manion@nih.gov
(301) 312-2103
Time Frame
Start Date: 2019-12-20
Estimated Completion Date: 2029-04-30
Participants
Target number of participants: 70
Treatments
1
Patients with TB who have already initiated treatment and are suspected to have paradoxical reactions, as well as patients taking TB treatment without signs of paradoxical reactions.
Related Therapeutic Areas
Sponsors
Leads: National Institute of Allergy and Infectious Diseases (NIAID)

This content was sourced from clinicaltrials.gov